A trial directly comparing two commonly used blood-thinning drugs found that one carries a lower risk of dangerous bleeding ...
By Jody Godoy PHILADELPHIA, March 17 (Reuters) - The U.S. Federal Trade Commission is on the lookout for anticompetitive ...
A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same class of medicines - ...
In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous ...
Boring is beautiful. That adage is especially true during turbulent times. If you haven't noticed, the current market and ...
Combining Trinity's high yield and Bristol Myers' defensive dividend growth can enhance both income and total return for ...
The COBRRA randomized trial that compared direct oral anticoagulants (DOACs) for acute venous thromboembolism (VTE), and ...
Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results